Herpes Zoster Vaccine 1437173A

Phase 3Vaccine

GSK

Herpes Zoster Vaccine 1437173A is one of 71 biologic programs targeting Immunodeficiency. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunodeficiencyActive, not recruiting

Genital HerpesActive, not recruiting

Herpes ZosterActive, not recruiting

ImmunodeficiencyPhase 2

Active, not recruiting

Genital HerpesPhase 3

Active, not recruiting

Herpes ZosterPhase 3

Active, not recruiting

Competition

Competitive Landscape

296 competitors in Immunodeficiency

#DrugCompanyPhaseTrials

Repatha

Amgen

Phase 3

1 2

Vemlidy

Gilead

Phase 3

—3

Valtrex

GGlaxo Dba Glaxosmithkline

Phase 3

1 4

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 5

Livalo

MMedicure

Phase 3

1 6

Igpro20

CSL Behring

Phase 3

2 7

BIC/FTC/TAF

Merck & Co.

Phase 3

5 8

PCV15

Merck & Co.

Phase 3

1 9

Herpes Zoster Vaccine 1437173A

GSK

Phase 3

1 10

BI201335

Boehringer Ingelheim

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Herpes Zoster18 trials

Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

Completed· GSK logo

GSK·Phase 3·NCT02045836·865 enrolled

Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults

Completed· GSK logo

GSK·Phase 1·NCT01086449·20 enrolled

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

Completed· GSK logo

GSK·Phase 3·NCT02690207·8,687 enrolled

Show 15 more trials

Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older

Completed· GSK logo

GSK·Phase 3·NCT01165229·14,819 enrolled

Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A

Completed· GSK logo

GSK·Phase 3·NCT01610414·1,877 enrolled

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant

Completed· GSK logo

GSK·Phase 3·NCT02058589·265 enrolled

Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older

Completed· GSK logo

GSK·Phase 3·NCT02735915·70 enrolled

Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years

Completed· GSK logo

GSK·Phase 3·NCT01777321·60 enrolled

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

Completed· GSK logo

GSK·Phase 2·NCT00802464·410 enrolled

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

Completed· GSK logo

GSK·Phase 3·NCT01954251·829 enrolled

Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older

Completed· GSK logo

GSK·Phase 3·NCT02052596·935 enrolled

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster

Completed· GSK logo

GSK·Phase 3·NCT01827839·96 enrolled

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

Completed· GSK logo

GSK·Phase 3·NCT01767467·568 enrolled

Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older

Completed· GSK logo

GSK·Phase 3·NCT01751165·354 enrolled

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

Completed· GSK logo

GSK·Phase 3·NCT02723773·7,539 enrolled

Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age

Completed· GSK logo

GSK·Phase 3·NCT02075515·651 enrolled

Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

Completed· GSK logo

GSK·Phase 3·NCT01165177·16,165 enrolled

Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A

Completed· GSK logo

GSK·Phase 2·NCT00920218·121 enrolled

Genital Herpes1 trial

Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease

Completed· GSK logo

GSK·Phase 3·NCT00699764·2,491 enrolled

Immunogenicity1 trial

Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects

Completed· GSK logo

GSK·Phase 2·NCT00434577·715 enrolled

Immunodeficiency1 trial

Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects

Completed· GSK logo

GSK·Phase 2·NCT01165203·123 enrolled

Immune Response1 trial

Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines

Completed· GSK logo

GSK·Phase 1/2·NCT00698490·130 enrolled

2 more indications

Herpes Simplex Virus1 trial

Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults

Completed· GSK logo

GSK·Phase 1·NCT00698893·16 enrolled

Herpes Simplex1 trial

Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive / Seronegative Subjects

Completed· GSK logo

GSK·Phase 3·NCT00698568·7,460 enrolled

Sources

References

[1]
ClinicalTrials.gov — 24 trial records for Herpes Zoster Vaccine 1437173A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Herpes Zoster Vaccine 1437173A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Herpes Zoster Vaccine 1437173A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: GSK

Herpes Zoster Vaccine 1437173A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Herpes Zoster18 trials

Genital Herpes1 trial

Immunogenicity1 trial

Immunodeficiency1 trial

Immune Response1 trial

Herpes Simplex Virus1 trial

Herpes Simplex1 trial

References

Drug Info

Quick Facts

Related News